JP2016501878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501878A5 JP2016501878A5 JP2015545601A JP2015545601A JP2016501878A5 JP 2016501878 A5 JP2016501878 A5 JP 2016501878A5 JP 2015545601 A JP2015545601 A JP 2015545601A JP 2015545601 A JP2015545601 A JP 2015545601A JP 2016501878 A5 JP2016501878 A5 JP 2016501878A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- group
- solution
- vwf
- factor viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 108010049003 Fibrinogen Proteins 0.000 claims 12
- 102000008946 Fibrinogen Human genes 0.000 claims 12
- 229940012952 fibrinogen Drugs 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 108010047303 von Willebrand Factor Proteins 0.000 claims 10
- 102100036537 von Willebrand factor Human genes 0.000 claims 10
- 229960001134 von willebrand factor Drugs 0.000 claims 10
- 108010054218 Factor VIII Proteins 0.000 claims 9
- 102000001690 Factor VIII Human genes 0.000 claims 9
- 229960000301 factor viii Drugs 0.000 claims 9
- 239000012539 chromatography resin Substances 0.000 claims 8
- 239000002994 raw material Substances 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 102000013566 Plasminogen Human genes 0.000 claims 3
- 108010051456 Plasminogen Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 3
- 208000002004 Afibrinogenemia Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 2
- 239000011347 resin Substances 0.000 claims 2
- 229920005989 resin Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
- DAPOMFMFTBUAKL-UHFFFAOYSA-N 2-ethylpyridine-3-thiol Chemical compound CCC1=NC=CC=C1S DAPOMFMFTBUAKL-UHFFFAOYSA-N 0.000 claims 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims 1
- 206010016075 Factor I deficiency Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 238000011067 equilibration Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733761P | 2012-12-05 | 2012-12-05 | |
| US61/733,761 | 2012-12-05 | ||
| EP13153898.5 | 2013-02-04 | ||
| EP13153898 | 2013-02-04 | ||
| US13/803,740 US20140154233A1 (en) | 2012-12-05 | 2013-03-14 | Method of purifying therapeutic proteins |
| US13/803,740 | 2013-03-14 | ||
| AU2013203357 | 2013-04-10 | ||
| AU2013203357A AU2013203357B2 (en) | 2012-12-05 | 2013-04-10 | A method of purifying therapeutic proteins |
| PCT/AU2013/001414 WO2014085861A1 (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178301A Division JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501878A JP2016501878A (ja) | 2016-01-21 |
| JP2016501878A5 true JP2016501878A5 (https=) | 2017-01-19 |
| JP6411360B2 JP6411360B2 (ja) | 2018-10-24 |
Family
ID=47630209
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545601A Active JP6411360B2 (ja) | 2012-12-05 | 2013-12-05 | 治療タンパク質の精製方法 |
| JP2018178301A Active JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
| JP2021016182A Active JP7774384B2 (ja) | 2012-12-05 | 2021-02-04 | 治療タンパク質の精製方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178301A Active JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
| JP2021016182A Active JP7774384B2 (ja) | 2012-12-05 | 2021-02-04 | 治療タンパク質の精製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20140154233A1 (https=) |
| EP (2) | EP2928905B1 (https=) |
| JP (3) | JP6411360B2 (https=) |
| KR (2) | KR102403847B1 (https=) |
| CN (2) | CN109125714B (https=) |
| AU (2) | AU2013203357B2 (https=) |
| BR (1) | BR112015012854B1 (https=) |
| CA (2) | CA2893373A1 (https=) |
| PL (1) | PL2928905T3 (https=) |
| RU (1) | RU2685956C2 (https=) |
| SG (2) | SG11201504372UA (https=) |
| WO (1) | WO2014085861A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX351340B (es) | 2012-03-13 | 2017-10-11 | Octapharma Ag | Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este. |
| US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
| GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| EP3400029B1 (en) * | 2016-01-07 | 2022-03-02 | Eio Biomedical Ltd | Compositions for reducing tissue adhesions |
| KR20190026000A (ko) | 2016-07-06 | 2019-03-12 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 안정적 액체 피브리노겐 |
| CN109789162A (zh) * | 2016-09-01 | 2019-05-21 | 普拉斯富瑞有限公司 | 具有降低的纤溶活性的人类血液源产品及其在止血障碍中的用途 |
| KR20250088663A (ko) * | 2017-08-23 | 2025-06-17 | 체에스엘 베링 게엠베하 | 폰 빌레브란트 인자의 바이러스 여과 방법 |
| IL317026A (en) * | 2018-02-28 | 2025-01-01 | Plas Free Ltd | In vitro device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof |
| CN109078628B (zh) * | 2018-08-27 | 2021-06-11 | 西北大学 | 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用 |
| FR3090321B1 (fr) | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
| MX2023000156A (es) * | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| JP2025512143A (ja) | 2020-11-09 | 2025-04-17 | 武田薬品工業株式会社 | 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製 |
| WO2022218962A1 (en) | 2021-04-13 | 2022-10-20 | Grifols Worldwide Operations Limited | Liquid composition comprising factor viii or factor viii/von willebrand factor complex |
| CN115181178B (zh) * | 2021-09-04 | 2024-04-26 | 广东双林生物制药有限公司 | 一种从冷沉淀中制备人纤维蛋白原的方法 |
| CN118401262A (zh) | 2021-12-30 | 2024-07-26 | 巴克斯特国际公司 | 用于纤维蛋白密封剂的纤维蛋白原和凝血酶溶液以及纤维蛋白密封剂试剂盒 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| FR2632309B1 (fr) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| EP0602173B1 (en) * | 1991-09-05 | 1999-05-26 | Baxter International Inc. | Topical fibrinogen complex |
| FR2686883B1 (fr) * | 1992-02-04 | 1994-05-13 | Aquitaine Develop Transf Sanguin | Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant. |
| ATE184884T1 (de) | 1994-07-14 | 1999-10-15 | Croix Rouge De Belgique | Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung |
| JPH10505496A (ja) * | 1994-09-02 | 1998-06-02 | ニューヨーク ブラッド センター，インコーポレイティド | 酵母による組換フィブリノーゲンの生産及び分泌 |
| US6037457A (en) * | 1997-01-31 | 2000-03-14 | The University Of North Carolina At Chapel Hill | Method for recombinant fibrinogen production |
| FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| DK1115745T3 (da) * | 1998-09-24 | 2006-10-02 | Pharming Intellectual Pty Bv | Oprensning af fibrinogen fra væsker ved udfældning og hydrofob interaktionskromatografi |
| NZ518692A (en) * | 1999-12-23 | 2004-08-27 | Csl Ltd | Purified fibrinogen free of destabilising levels of plasminogen and other proteases obtained from a Fraction I paste |
| EP1220781A4 (en) | 1999-12-23 | 2007-04-18 | Rodger H Rast | SYSTEM AND METHOD FOR PROVIDING INDIVIDUALIZED DOSAGE |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| AU2002314081B2 (en) * | 2001-05-21 | 2007-04-05 | Omrix Biopharmaceuticals S.A. | Removal pf plasmin(Ogen) from protein solutions |
| AUPR638801A0 (en) | 2001-07-13 | 2001-08-09 | Life Therapeutics Limited | Factor viii separation |
| IL161261A0 (en) * | 2001-10-03 | 2004-09-27 | Christopher J Woolverton | Storage-stable fibrinogen solutions |
| AU2002340776A1 (en) * | 2001-10-30 | 2003-05-12 | Novozymes A/S | High throughput isolation of proteins by charge induction chromatography |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| WO2003102132A2 (en) | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
| GB0216001D0 (en) | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
| DE10246125A1 (de) | 2002-10-01 | 2004-04-15 | Aventis Behring Gmbh | Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren |
| ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
| DE102004009400A1 (de) * | 2004-02-24 | 2005-09-08 | Zlb Behring Gmbh | Fibrinogen Reinigung |
| US20070142629A1 (en) * | 2004-06-16 | 2007-06-21 | Ciphergen Biosystems, Inc. | Multichemistry fractionation |
| EP2102335B1 (en) * | 2007-01-04 | 2012-02-22 | Crucell Holland B.V. | Purification of factor xi |
| CN101730707B (zh) | 2007-07-11 | 2014-12-17 | 诺沃-诺迪斯克有限公司 | 使用混合式或多模式树脂来纯化因子ⅷ |
| EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
| KR20100103595A (ko) | 2008-01-18 | 2010-09-27 | 에프. 호프만-라 로슈 아게 | 비-글라이코실화된 단백질의 정제 |
| EP2300497B1 (en) | 2008-06-24 | 2012-08-08 | Octapharma AG | A process of purifying coagulation factor viii |
| ES2524886T3 (es) * | 2010-01-08 | 2014-12-15 | Profibrix Bv | Preparados de fibrinógeno enriquecidos en fibrinógeno con una cadena alfa extendida |
| RU2603103C2 (ru) | 2010-09-20 | 2016-11-20 | Октафарма Аг | Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт |
| SG191071A1 (en) * | 2010-12-08 | 2013-07-31 | Amgen Inc | Ion exchange chromatography in the presence of an amino acid |
| MX351340B (es) | 2012-03-13 | 2017-10-11 | Octapharma Ag | Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este. |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
-
2013
- 2013-03-14 US US13/803,740 patent/US20140154233A1/en not_active Abandoned
- 2013-04-10 AU AU2013203357A patent/AU2013203357B2/en active Active
- 2013-12-05 CA CA2893373A patent/CA2893373A1/en not_active Abandoned
- 2013-12-05 EP EP13861334.4A patent/EP2928905B1/en active Active
- 2013-12-05 SG SG11201504372UA patent/SG11201504372UA/en unknown
- 2013-12-05 EP EP18207150.6A patent/EP3483173A1/en active Pending
- 2013-12-05 BR BR112015012854-8A patent/BR112015012854B1/pt active IP Right Grant
- 2013-12-05 PL PL13861334T patent/PL2928905T3/pl unknown
- 2013-12-05 WO PCT/AU2013/001414 patent/WO2014085861A1/en not_active Ceased
- 2013-12-05 KR KR1020217010484A patent/KR102403847B1/ko active Active
- 2013-12-05 CN CN201811091750.9A patent/CN109125714B/zh active Active
- 2013-12-05 SG SG10201704484QA patent/SG10201704484QA/en unknown
- 2013-12-05 CN CN201380063945.1A patent/CN104981476B/zh active Active
- 2013-12-05 AU AU2013354899A patent/AU2013354899B2/en active Active
- 2013-12-05 RU RU2015126551A patent/RU2685956C2/ru active
- 2013-12-05 CA CA3185085A patent/CA3185085A1/en active Pending
- 2013-12-05 JP JP2015545601A patent/JP6411360B2/ja active Active
- 2013-12-05 KR KR1020157017824A patent/KR102240978B1/ko active Active
-
2014
- 2014-11-06 US US14/535,085 patent/US9598461B2/en active Active
-
2017
- 2017-02-03 US US15/424,072 patent/US20170143805A1/en not_active Abandoned
-
2018
- 2018-09-25 JP JP2018178301A patent/JP6836562B2/ja active Active
- 2018-12-10 US US16/214,519 patent/US11426680B2/en active Active
-
2021
- 2021-02-04 JP JP2021016182A patent/JP7774384B2/ja active Active
- 2021-03-01 US US17/188,173 patent/US20210283530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501878A5 (https=) | ||
| Franchini et al. | The history of hemophilia | |
| RU2015126551A (ru) | Способ очистки лечебных белков | |
| Berntorp et al. | Modern haemophilia care | |
| Walsh et al. | The burden of inhibitors in haemophilia patients | |
| Teoh et al. | p53 abnormalities and potential therapeutic targeting in multiple myeloma | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2018521135A5 (https=) | ||
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| ES2829923T3 (es) | Un proceso novedoso de purificación para el aislamiento y la producción comercial de tnk-tpa recombinante (tenecteplase) | |
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| CN102584983A (zh) | 一种分离纯化凝血因子viii的方法 | |
| Ettingshausen et al. | The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? | |
| Santagostino | A new recombinant factor VIII: from genetics to clinical use | |
| JP2015514115A5 (https=) | ||
| RU2015121574A (ru) | Препарат для биспецифических активаторов т-клеток(bite) | |
| K. Lau et al. | Thrombotic complications of neonates and children with congenital nephrotic syndrome | |
| Di Minno et al. | Management of patients with long‐term inhibitors: is immune tolerance an underestimated life‐long solution? | |
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Goubran et al. | New monoclonal/bi-specific antibodies: reshaping transfusion medicine beyond replacement | |
| JP2008517046A5 (https=) | ||
| Ofosu et al. | The fraction of recombinant factor VIII: Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro | |
| CN104560925A (zh) | 一种从人凝血因子ⅸ层析废液中激活制备人凝血酶的方法 | |
| Ilhan et al. | Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategies |